Short Interest in Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Grows By 113.1%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 745,300 shares, an increase of 113.1% from the February 28th total of 349,800 shares. Currently, 7.5% of the company’s stock are short sold. Based on an average daily trading volume, of 7,170,000 shares, the days-to-cover ratio is presently 0.1 days.

Petros Pharmaceuticals Stock Down 22.5 %

PTPI traded down $0.03 during midday trading on Friday, hitting $0.09. 19,121,165 shares of the company’s stock traded hands, compared to its average volume of 9,052,678. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.85 and a quick ratio of 0.74. The company has a market cap of $973,434.00, a PE ratio of -0.02 and a beta of 2.04. The stock’s fifty day simple moving average is $0.18 and its 200-day simple moving average is $0.28. Petros Pharmaceuticals has a one year low of $0.05 and a one year high of $1.48.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).